Domiciliary nebulized terbutaline in severe chronic airways obstruction

Forty-eight patients with severe chronic airways obstruction were given 5 mg terbutaline or placebo from a nebulizer twice daily for 2 + 2 weeks. Twenty three patients preferred terbutaline, 9 placebo and 16 had no preference. The baseline lung function and the 6 minute walking distance were not increased after the terbutaline period. The patients who preferred terbutaline indicated less dyspnoea after the terbutaline period as compared to the placebo period, but did not differ with regard to lung function or walking distance after the terbutaline treatment. The physiology behind the subjective relief from the terbutaline inhalations remains unexplained.

This article has been cited by other articles:

				V. Pepin, J. Brodeur, Y. Lacasse, J. Milot, P. LeBlanc, F. Whittom, and F. Maltais Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease Thorax, April 1, 2007; 62(4): 291 - 298. [Abstract] [Full Text] [PDF]

				F S F Ram and P Sestini Regular inhaled short acting {beta}2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis Thorax, July 1, 2003; 58(7): 580 - 584. [Abstract] [Full Text] [PDF]

				J. J. W. Liesker, P. J. Wijkstra, N. H. T. Ten Hacken, G. H. Koeter, D. S. Postma, and H. A. M. Kerstjens A Systematic Review of the Effects of Bronchodilators on Exercise Capacity in Patients With COPD Chest, February 1, 2002; 121(2): 597 - 608. [Abstract] [Full Text] [PDF]